Clinical trials: sponsored by Bayer
Bronchitis, Chronic, Bronchial Diseases
Greatest International Antiinfective Trial With Avelox
The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit…
- Trial name
- GIANT (NCT00932802)
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 24 sites in Austria, Brazil and 22 more
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Skin Diseases, Bacterial
Avelox in Complicated Skin and Skin Structure Infections
This international, prospective, non-interventional, non-controlled observational study obtains data on efficacy, safety and tolerability of Avelox treatment under daily-life treatment conditions.
- Trial name
- ARTOS (NCT00997997)
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 12 sites in Austria, Bulgaria and 10 more
- Volunteers
- 6,127 people
- Sponsor
- Bayer
Infection
Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution
This study is a post-marketing surveillance in Japan to investigate the safety especially focusing on injection site adverse events and efficacy in patients with Ciprofloxacin iv administration without dilution in the daily…
- Trial name
- NCT01690559
- Testing
- Cipro (Ciprofloxacin, BAYQ3939)
- Where
- Japan
- Volunteers
- 704 people
- Sponsor
- Bayer
Liver
Primovist Regulatory Post Marketing Surveillance (PMS)
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice
- Trial name
- NCT00924248
- Testing
- Gadoxetic acid disodium (Primovist, BAY86-4873)
- Where
- South Korea
- Volunteers
- 4,358 people
- Sponsor
- Bayer
Infection
Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance
This study is a post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Ciproxan intravenously as a first-line treatment for sepsis, secondary skin infections…
- Trial name
- NCT01670435
- Testing
- Ciprofloxacin (BAYQ3939)
- Where
- Japan
- Volunteers
- 3,274 people
- Sponsor
- Bayer
Hemophilia A
EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan
The aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer/FS in treatment of patients with…
- Trial name
- NCT00932555
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- Taiwan
- Volunteers
- 82 people
- Sponsor
- Bayer
Non-Hodgkin's Lymphoma (NHL)
Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan
This study is a regulatory post-marketing surveillance of Zevalin (ibritumomab tiuxetan) in Japan. In-111 Zevalin is, at first, injected to patient for gamma scan imaging to assess biodistribution of the Zevalin.
- Trial name
- ZEVALIN-SDUI (NCT01479387)
- Testing
- [111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Diagnostic Imaging
Magnevist Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Magnevist at a dose of more than 0.2 ml/kg for MR angiography of peripheral…
- Trial name
- NCT01376739
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- Japan
- Volunteers
- 2,051 people
- Sponsor
- Bayer
Hemophilia A
Prophylaxis Versus On-demand Therapy Through Economic Report
The project is a controlled observational, multicenter, prospective data collection on secondary prophylaxis with Kogenate Bayer in adolescents and adults with severe haemophilia A (FVIII < 1%).
- Trial name
- POTTER (NCT01159587)
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Bayer
Diagnostic Imaging
PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination
The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study.
- Trial name
- IMAGE (NCT00876083)
- Testing
- Ultravist (Iopromide, BAY86-4877)
- Where
- 21 sites in Bosnia and Herzegovina, China and 19 more
- Volunteers
- 44,920 people
- Sponsor
- Bayer
Hemophilia
BAY14-2222 Continuous Infusion in Surgeries
Phase III study, to evaluate the efficacy and safety of continuous infusion of rFVIII-FS in the treatment of patients with hemophilia A undergoing major elective surgery by achieving the required therapeutic concentrations.
- Trial name
- NCT00606060
- Testing
- Kogenate (BAY14-2222)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Bayer
Hemophilia A
International PMS Study - KOGENATE Bayer
To evaluate long-term safety (primarily by recording adverse events including inhibitors), efficacy and patient acceptance of KOGENATE Bayer in home treatment either on prophylaxis or on demand.
- Trial name
- NCT00864552
- Testing
- Kogenate (BAY14-2222)
- Where
- 10 sites in Austria, Belgium and 8 more
- Volunteers
- 200 people
- Sponsor
- Bayer